Union Demands Sanofi Retain Control of Doliprane Production
In a significant development for the French pharmaceutical industry, union representatives gathered at the Lisieux production site of Doliprane, the country's best-selling drug, to demand that its manufacturer, Opella, remains under the control of its parent company, Sanofi. This call comes in light of Sanofi's recent announcement regarding negotiations with the American investment fund CD&R for the potential sale of Opella. The unions express deep concern over the implications this sale might have on France's health sovereignty and the future of local jobs.
During a visit by Economy Minister Antoine Armand and Industry Minister Marc Ferracci, union delegates voiced their strong opposition to the sale, highlighting the importance of keeping Doliprane production in France. CFDT coordinator within Sanofi stated, "For us, it's very simple; we are asking that Opella remains under the control of Sanofi."
Government's Commitment to Local Production
Minister Antoine Armand emphasized the government's commitment to ensuring that Doliprane continues to be produced in France. He stated that he would seek "extremely strong guarantees" from any potential buyers to ensure that production remains local. As he addressed the media, he reassured the public that the government is prepared to take necessary measures to block the sale if adequate assurances are not provided. "My commitment is that Doliprane will continue to be produced in France, by employees in France," he asserted.
Political and Public Response
The controversy surrounding the potential sale has sparked a wave of criticism from opposition parties, who argue that it poses a threat to France's industrial sovereignty. Many politicians have echoed the unions' concerns, urging the government to refuse the sale and maintain national control over essential pharmaceutical activities. The visit to Lisieux aimed to calm the unrest and demonstrate the government's proactive stance on the matter, as union members and local politicians gathered to express their solidarity with the workers.
As the situation unfolds, the future of Doliprane production in France hangs in the balance, with both the government and unions advocating for its continued local manufacturing.
